<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265876</url>
  </required_header>
  <id_info>
    <org_study_id>I173</org_study_id>
    <secondary_id>CAN-NCIC-IND173</secondary_id>
    <secondary_id>ZENECA-CAN-NCIC-IND173</secondary_id>
    <secondary_id>CDR0000450844</secondary_id>
    <nct_id>NCT00265876</nct_id>
  </id_info>
  <brief_title>AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>A Phase I/II Study of AZD0530 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to&#xD;
      stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving AZD0530 together with gemcitabine may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of AZD0530 when&#xD;
      given together with gemcitabine and to see how well they work in treating patients with&#xD;
      locally advanced or metastatic pancreatic cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Phase I&#xD;
&#xD;
        -  Determine the maximum tolerated dose of AZD0530 when given in combination with&#xD;
           gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic&#xD;
           cancer.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine toxicity profile and dose-limiting toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine pharmacokinetic profile of this regimen in these patients.&#xD;
&#xD;
        -  Correlate the toxicity profile with the pharmacokinetics of this regimen in these&#xD;
           patients.&#xD;
&#xD;
      Phase II&#xD;
&#xD;
        -  Determine the objective response rate (partial and complete response) and prolonged&#xD;
           stable disease rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the median survival, 1-year survival, response or stable disease duration,&#xD;
           time to disease progression, clinical benefit response, and progression-free survival of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Correlate changes in serum CTX levels (post-treatment vs baseline) with response and&#xD;
           other clinical outcomes in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a phase I, open-label, multicenter, dose-escalation study of AZD0530&#xD;
      followed by a phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive oral AZD0530 once daily on days 1-28 and gemcitabine IV over&#xD;
           30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in&#xD;
           the absence of disease progression or unacceptable toxicity. Patients receive 2&#xD;
           additional courses after achieving complete response or stable partial response.&#xD;
           Patients with ongoing stable disease receive up to 6 courses. Patients who discontinue&#xD;
           gemcitabine due to unacceptable toxicity or who complete 6 courses of therapy may&#xD;
           continue to receive AZD0530 alone in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of AZD0530 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.&#xD;
&#xD;
        -  Phase II: Patients receive AZD0530 at the MTD determined in phase I and gemcitabine as&#xD;
           in phase I.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2005</start_date>
  <completion_date type="Actual">January 6, 2012</completion_date>
  <primary_completion_date type="Actual">January 8, 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response (complete [CR] and partial response [PR] or stable disease [SD]) at 8 weeks</measure>
    <time_frame>4 years</time_frame>
    <description>Response is assessed every other cycle and will be reported on at final analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>4 years</time_frame>
    <description>Toxicity is assessed from the time of first treatment and final results will be reported at final analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>AZD0530 + Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0530</intervention_name>
    <description>Taken daily every 4 weeks</description>
    <arm_group_label>AZD0530 + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>1000mg/m2 IV weekly</description>
    <arm_group_label>AZD0530 + Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed pancreatic adenocarcinoma&#xD;
&#xD;
               -  Unresectable disease&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Clinically or radiologically documented disease&#xD;
&#xD;
               -  Measurable or evaluable disease (phase I)&#xD;
&#xD;
               -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by&#xD;
                  conventional techniques OR ≥ 10 mm by spiral CT scan (phase II)&#xD;
&#xD;
                    -  Measurable lesion must be outside of previously irradiated field if it is&#xD;
                       the sole site of disease unless there is documented disease progression&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2 times upper limit of normal (ULN) (5 times ULN if clearly attributable&#xD;
             to liver metastasis)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No active cardiomyopathy&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary disease requiring oxygen supplementation&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  Must not require IV hyperalimentation&#xD;
&#xD;
          -  No uncontrolled inflammatory gastrointestinal (GI) disease (e.g., Crohn's disease or&#xD;
             ulcerative colitis)&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No postsurgical malabsorption characterized by uncontrolled diarrhea that results in&#xD;
             weight loss and vitamin deficiency&#xD;
&#xD;
          -  No other GI tract disease resulting in an inability to take oral medications&#xD;
&#xD;
          -  Must be able to take oral medication without crushing, dissolving, or chewing tablets&#xD;
&#xD;
          -  Pancreatic enzyme supplementation allowed provided the above conditions are met&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No immune deficiency&#xD;
&#xD;
          -  No active, uncontrolled, or serious infection&#xD;
&#xD;
          -  No know hypersensitivity to study drugs or their components&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of psychiatric illness (e.g., uncontrolled psychotic disorders) or&#xD;
             neurologic disorder that would preclude study compliance&#xD;
&#xD;
          -  No other serious medical condition or illness that would preclude study participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated nonmelanomatous&#xD;
             skin cancer or carcinoma in situ of the cervix or bladder&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy except fluorouracil (with or without leucovorin calcium) or&#xD;
             gemcitabine given concurrently with radiotherapy as a radiosensitizer&#xD;
&#xD;
               -  At least 4 weeks since prior fluorouracil or gemcitabine&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent systemic hormonal therapy for symptom control (e.g., appetite stimulation,&#xD;
             pain, or nausea) allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy for local disease and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 2 weeks since prior anticancer therapy or investigational agents&#xD;
&#xD;
          -  The following drugs must not be used for 1-2 weeks before, during, and for 1-2 weeks&#xD;
             after completion of study treatment:&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Mibefradil&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Saquinavir mesylate&#xD;
&#xD;
               -  Indinavir sulfate&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Nefazodone hydrochloride&#xD;
&#xD;
               -  Fluconazole&#xD;
&#xD;
               -  Diltiazem hydrochloride&#xD;
&#xD;
               -  Alfentanil hydrochloride&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Cyclosporine&#xD;
&#xD;
               -  Tacrolimus&#xD;
&#xD;
               -  Lovastatin&#xD;
&#xD;
               -  Simvastatin&#xD;
&#xD;
               -  Any other drug known to be a potent inhibitor of cytochrome 3A4&#xD;
&#xD;
          -  No other concurrent anticancer therapy or investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm J. Moore, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharlene Gill, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E, Walde D, Goel R, Southwood B, Gauthier I, Walsh W, McIntosh L, Seymour L. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2012 Apr;30(2):779-86. doi: 10.1007/s10637-010-9611-3. Epub 2010 Dec 18.</citation>
    <PMID>21170669</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Saracatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

